Firstline treatment with ruxolitinib versus best available therapy in patients with polycythemia vera: results from the randomized RuxoBEAT trial.

Koschmieder S, Isfort S, Teichmann LL, Schafhausen P, Heidel FH, Crodel C, Hochhaus A, Griesshammer M, Sockel K, Jost PJ, Walther D, Döhner K, Göthert JR, Radsak M, Augustin M, Becker H, Giagounidis A, Schaich M, Klausmann M, von Bubnoff N, Stegelmann F, Kortmann M, Zentis M, Frank J, Hagemeier A, Hellmich M, Brümmendorf TH, German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

Open source

DOI: 10.1038/s41408-026-01644-2
Published: 2026 Oct 22
Container: Blood cancer journal
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41408-026-01644-2,
  title = {Firstline treatment with ruxolitinib versus best available therapy in patients with polycythemia vera: results from the randomized RuxoBEAT trial.},
  author = {Koschmieder S and Isfort S and Teichmann LL and Schafhausen P and Heidel FH and Crodel C and Hochhaus A and Griesshammer M and Sockel K and Jost PJ and Walther D and Döhner K and Göthert JR and Radsak M and Augustin M and Becker H and Giagounidis A and Schaich M and Klausmann M and von Bubnoff N and Stegelmann F and Kortmann M and Zentis M and Frank J and Hagemeier A and Hellmich M and Brümmendorf TH and German Study Group for Myeloproliferative Neoplasms (GSG-MPN)},
  year = {2026},
  journal = {Blood cancer journal},
  doi = {10.1038/s41408-026-01644-2},
  url = {https://doi.org/10.1038/s41408-026-01644-2}
}

RIS

TY  - JOUR
TI  - Firstline treatment with ruxolitinib versus best available therapy in patients with polycythemia vera: results from the randomized RuxoBEAT trial.
AU  - Koschmieder S
AU  - Isfort S
AU  - Teichmann LL
AU  - Schafhausen P
AU  - Heidel FH
AU  - Crodel C
AU  - Hochhaus A
AU  - Griesshammer M
AU  - Sockel K
AU  - Jost PJ
AU  - Walther D
AU  - Döhner K
AU  - Göthert JR
AU  - Radsak M
AU  - Augustin M
AU  - Becker H
AU  - Giagounidis A
AU  - Schaich M
AU  - Klausmann M
AU  - von Bubnoff N
AU  - Stegelmann F
AU  - Kortmann M
AU  - Zentis M
AU  - Frank J
AU  - Hagemeier A
AU  - Hellmich M
AU  - Brümmendorf TH
AU  - German Study Group for Myeloproliferative Neoplasms (GSG-MPN)
PY  - 2026
JO  - Blood cancer journal
DO  - 10.1038/s41408-026-01644-2
UR  - https://doi.org/10.1038/s41408-026-01644-2
ER  -

APA

S, K., S, I., LL, T., P, S., FH, H., C, C., A, H., M, G., K, S., PJ, J., D, W., K, D., JR, G., M, R., M, A., H, B., A, G., M, S., M, K., N, V. B., F, S., M, K., M, Z., J, F., A, H., M, H., TH, B., & (GSG-MPN), G. S. G. F. M. N. (2026). Firstline treatment with ruxolitinib versus best available therapy in patients with polycythemia vera: results from the randomized RuxoBEAT trial.. Blood cancer journal. https://doi.org/10.1038/s41408-026-01644-2

Source records

pubmed · retrieved 2026-11-10T12:15:14.301Z
europe-pmc · retrieved 2026-11-10T12:15:14.316Z
doaj · retrieved 2026-11-10T12:15:14.317Z